Australia markets closed

HOMOLOGY MED. DL-,0001 (35H.MU)

Munich - Munich Delayed price. Currency in EUR
Add to watchlist
6.300.00 (0.00%)
As of 8:00AM CEST. Market open.
Full screen
Previous close6.30
Open6.30
Bid5.85 x 0
Ask6.40 x 0
Day's range6.30 - 6.30
52-week range6.30 - 17.27
Volume70
Avg. volume1
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer
    GlobeNewswire

    Homology Medicines Announces Promotion of Tim Kelly to Chief Operating Officer

    - Built Internal GMP Commercial Process and Manufacturing Platform and Scaled HEK293 Suspension System to 2,000L Under His Leadership - BEDFORD, Mass., April 12, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Tim Kelly has been promoted to Chief Operating Officer, effective immediately. Previously, Mr. Kelly held the role of Chief Technical Operations Officer and led the construction of the Company’s internal 25,000-square-foot GMP manufacturing facility, which was completed in 12 months from design to operation. As one of the first companies to scale to a 2,000-liter bioreactor with a HEK293 serum-free suspension system, Homology’s commercial scale process and platform gives the Company the ability to produce large scale volumes to support its gene therapy and editing programs, and can be further leveraged to target larger disease areas. “From the beginning, Tim was a major driver behind the strategic decision to invest in developing our process and internal manufacturing capabilities, including realizing the value of operating under the same roof as our research and process development labs,” stated Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines. “Tim’s more than 20 years of technical knowledge and business operations experience has been key to progressing our dual gene therapy and editing platform, and we look forward to his broader contributions to our organization as we continue to advance our mission to bring genetic medicines to patients.” Under his leadership, Homology has attracted and grown a highly experienced technical operations team, some of whom worked alongside Mr. Kelly in developing the first commercially approved, single-use bioreactor manufacturing system many years ago while at Shire plc. This experience, coupled with Tim’s strategic vision, enabled the rapid development and optimization of Homology’s “plug and play” platform that currently serves all programs, regardless of the modality or transgene. With 3,500 liters of total capacity, Homology is advancing its Phase 2 pheNIX gene therapy clinical trial, for which it expects to report initial data by the end of this year, and plans to initiate two other clinical programs, including its first gene editing trial. Mr. Kelly is an industry leader with a successful track record that spans senior roles at Shire plc, Sarepta Therapeutics, Inc., Biogen Idec and UCB S.A. He has been featured in many industry articles and panels and plans to participate in the upcoming 5th Annual Chardan Genetic Medicines Manufacturing Summit taking place on Tuesday, April 27 at 1:00 p.m. ET, where he will present on Homology’s manufacturing process and platform. About Homology Medicines, Inc. Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases. The Company’s intellectual property covers its family of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines. For more information, please visit www.homologymedicines.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans and timing for the release of clinical data and for the initiation of additional clinical programs; our beliefs regarding our manufacturing capabilities; our position as a leader in the development of genetic medicines; and participation in upcoming presentations and conferences. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: the impact of the COVID-19 pandemic on our business and operations, including our preclinical studies and clinical trials, and on general economic conditions; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; failure to identify additional product candidates and develop or commercialize marketable products; the early stage of our development efforts; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the capabilities of our manufacturing facility; risks relating to the regulatory approval process; our product candidates may cause serious adverse side effects; initial, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; failure to obtain U.S. or international marketing approval; ongoing regulatory obligations; effects of significant competition; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; product liability lawsuits; failure to attract, retain and motivate qualified personnel; the possibility of system failures or security breaches; risks relating to intellectual property and significant costs as a result of operating as a public company. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2020 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. Company ContactsTheresa McNeelyChief Communications Officer and Patient Advocatetmcneely@homologymedicines.com781-301-7277 Media Contact:Marisa CitranoSenior Corporate Communications Associatemcitrano@homologymedicines.com617-335-2841

  • Why Homology Medicines Stock Is Sinking Today
    Motley Fool

    Why Homology Medicines Stock Is Sinking Today

    Shares of Homology Medicines (NASDAQ: FIXX) were sinking 17.8% lower as of 12:01 p.m. EDT on Wednesday. The decline came after the company announced the pricing of its latest public stock offering. Biotech stocks usually fall after public stock offerings are announced.

  • Homology Medicines Announces Pricing of Public Offering of Common Stock
    GlobeNewswire

    Homology Medicines Announces Pricing of Public Offering of Common Stock

    BEDFORD, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a clinical-stage genetic medicines company, today announced the pricing of an underwritten public offering for proceeds of approximately $50.0 million, before deducting estimated offering expenses payable by Homology. Homology also granted the underwriter a 30-day option to purchase up to an additional $7.5 million of shares of its common stock. All of the shares in the offering are to be sold by Homology. BTIG is the sole book-running manager for the offering. The offering is expected to close on or about April 9, 2021, subject to customary closing conditions. Homology intends to use the net proceeds from the offering, in addition to its existing cash resources, to: continue to advance its lead gene therapy candidate, HMI-102, for the treatment of phenylketonuria (PKU) in adults through the ongoing Phase 2 pheNIX clinical trial; advance HMI-203, its gene therapy candidate for the treatment of Hunter syndrome, and HMI-103, its first gene editing candidate, which is for the treatment of PKU in the pediatric population, through IND-enabling studies and into clinical trials; advance its other pipeline programs through preclinical development; further expand its intellectual property portfolio; potentially further expand its manufacturing capacity; and for working capital and general corporate and administrative expenses.The securities described are being offered by Homology pursuant to a shelf registration statement on Form S-3 (Reg. No. 333-237131), including a base prospectus, which was declared effective by the Securities and Exchange Commission (SEC). The securities are being offered only by means of a prospectus supplement and accompanying prospectus forming a part of the effective registration statement. A preliminary prospectus supplement related to and describing the terms of the offering was filed with the SEC on April 6, 2021. The final prospectus related to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained, when available, from BTIG, LLC, 65 East 55th Street, New York, NY, 10022, by email at prospectusdelivery@btig.com or by telephone at (212) 593-7555. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Homology Medicines, Inc. Homology Medicines, Inc. is a clinical-stage genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Forward-Looking StatementsThis press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the completion and anticipated use of proceeds of the offering. All such forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties related to fluctuations in Homology’s stock price, changes in market conditions and satisfaction of customary closing conditions related to the public offering, as well as the other factors discussed in the “Risk Factors” section in the prospectus supplement and registration statement referenced above and in Homology’s most recently filed Annual Report on Form 10-K, as well as other risks detailed in Homology’s filings with the Securities and Exchange Commission. There can be no assurance that Homology will be able to complete the public offering on the anticipated terms. All information in this press release is as of the date of the release, and Homology undertakes no duty to update this information, even if subsequent events cause its views to change, unless required by law. Company ContactTheresa McNeelyChief Communications Officer and Patient Advocatetmcneely@homologymedicines.com781-301-7277